ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases
Picture Gallery, Venture Capital Wednesday, May 17th, 2017
Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials
